Company Profile

Potentia Pharmaceuticals Inc
Profile last edited on: 12/23/2014      CAGE: 47XY6      UEI: N8TMNBBJAH86

Business Identifier: Novel mechanisms to inhibit inflammation
Year Founded
2001
First Award
2004
Latest Award
2009
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6400 Westwind Way Suite A
Crestwood, KY 40014
   (502) 241-4114
   pascal@potentiapharma.com
   www.apellis.com
Location: Single
Congr. District: 04
County: Oldham

Public Profile

In November of 2014, Apellis Pharmaceuticals acquired Potentia Pharmaceuticals. Potentia Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing innovative therapeutics primarily in the area of age-related macular degeneration and other inflammatory ocular diseases. Potentia assembles its pipeline of anti-inflammatory products through a combination of in-licensing of preclinical compounds and in-house research and development.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
15-19

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2009 2 NIH $1,320,070
Project Title: Targeting drug-delivery nanoparticles to sites of inflammation
2006 1 NIH $293,017
Project Title: Preventing choroidal neovascularization by long-term transscleral drug delivery
2005 2 NIH $504,000
Project Title: Bypassing fluidics in proteomic screening
2004 1 NIH $252,798
Project Title: Modified bacterial system for vivo direction evolution

Key People / Management

  Cedric Francois -- Co-founder & Chief Executive Officer/President

  Puran S Bora

  Pascal Deschatelets

  Henry J Kaplan

  Paul K Olson

  Jason Slatker -- Chief Medical Officer